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Background. Recent guidelines recommend a target
hemoglobin range of 11 to 12 g/dL in pediatric and adult dialy-
sis patients. We compared anemia prevalence in United States
Medicare pediatric and adult dialysis patients.
Methods. Prevalent hemodialysis patients (0 to 19 years, pe-
diatric: N = 1692; adult: N = 352,291) and peritoneal dialysis
patients (pediatric: N = 597; adult: N = 39,136) treated with re-
combinant human erythropoietin (rHuEPO) from 1996 to 2000
were selected. Mean annual hemoglobin values were calculated
by modality, age, sex, and race.
Results. Among hemodialysis patients, mean annual
hemoglobin values less than 11 g/dL were present in pediatric
and adult patients during 54.1% versus 39.8% patient years, re-
spectively (P < 0.0001); for peritoneal dialysis patients, 69.5%
versus 55.1% (P < 0.0001). Mean hemoglobin values increased
over time and were 11.2, 11.5, 10.8, and 11.2 g/dL for pedi-
atric and adult hemodialysis and peritoneal dialysis patients,
respectively, in 2000. Pediatric hemodialysis patients received
intravenous iron less frequently than adults (66.3% vs. 82.5%
patient years; P < 0.0001).
Conclusion. Hemoglobin values in rHuEPO-treated pedi-
atric dialysis patients lagged behind those of adult patients, with
pediatric patients achieving target hemoglobin values only a mi-
nority of the time (45.9% and 30.5% patient years, respectively,
for hemodialysis and peritoneal dialysis). Trends show recent
improvement in anemia treatment of children on dialysis. Still,
further attention to and analysis of rHuEPO and iron therapy
in pediatric dialysis patients is warranted.
Anemia is a major consequence of chronic kidney dis-
ease. When severe, it is associated with cardiovascular
dysfunction, cardiomyopathy, and death [1–4]. As we re-
cently reported, cardiomyopathy incidence is increasing
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in pediatric chronic dialysis patients in the United States
[5]. These findings led us to our current study of anemia
in children receiving dialysis.
The major cause of anemia in patients with chronic
kidney disease and end-stage renal disease (ESRD)
is erythropoietin deficiency resulting from decreased
production of the kidneys [6, 7]. In 1989, recombinant
human erythropoietin (rHuEPO) became available in
the United States for the treatment of anemia due to
ESRD [8]. Correction of anemia in children with ESRD
improves cardiac dysfunction and exercise tolerance and
reduces left ventricular hypertrophy [9–11]. In 1997, the
National Kidney Foundation recommended a
hemoglobin range of 11 to 12 g/dL (hematocrit, 33% to
36%) for chronic dialysis patients [12]. The updated
guidelines include similar recommendations and some
discussion of treatment to higher hemoglobin values,
provided that evidence is published showing that such
treatment further reduces the potential for cardiac
complications [13].
Detailed data are not available on the frequency and
extent to which anemia is present over time in pediatric
dialysis patients. Therefore, we investigated hemoglobin
values in these patients, and in adult Medicare dialysis
patients receiving rHuEPO to determine the prevalence
of anemia.
METHODS
Data and sources
Using data from the United States Renal Data Sys-
tem, we studied the 1996 to 2000 period prevalent Medi-
care hemodialysis and peritoneal dialysis patients. The
period prevalent cohort for each year included both point
prevalent patients (who received ESRD treatment on
January 1 of the year and whose first ESRD service date
was ≥90 days before January 1), and incident patients
(who reached day 91 of ESRD between January 1 and
December 31 of the year). The follow-up period was de-
fined as the time from the start of follow-up until the
266
Chavers et al: Anemia in pediatric chronic dialysis patients 267
earliest of the following: date of death, modality change,
loss to follow-up, or December 31 of the year. Demo-
graphic data, including age, sex, race, and primary cause
of ESRD, were obtained from the Identification and Med-
ical Evidence sections of the Renal Beneficiary Utiliza-
tion System of the Centers for Medicare and Medicaid
Services. Patients with Medicare as a secondary payer,
or coverage from a health maintenance organization,
were excluded because data on rHuEPO use, hemoglobin
values, or intravenous iron use were incomplete.
Data on patient hematocrit values, rHuEPO dose, and
administration of intravenous iron were obtained from
institutional outpatient Medicare claims from January 1,
1996, to December 31, 2000. Included patients had at least
one rHuEPO claim during the follow-up period. For each
patient, the mean annual hematocrit value was calculated
from all rHuEPO claims during each year of follow-up.
Hemoglobin values were then calculated by dividing the
mean hematocrit value by three. Claims occurring dur-
ing the follow-up period also yielded data on the use of
intravenous iron, including iron dextran and ferric glu-
conate, which became available for use in 2000. However,
the use of ferric gluconate in 2000 may be underreported
because a national claims code for this product was not
available until 2001. Patients were defined as treated with
intravenous iron if they had received at least one admin-
istration of intravenous iron during each follow-up year.
Data analysis
By treatment modality (hemodialysis, peritoneal dial-
ysis), characteristics of 1996 to 2000 combined prevalent
patients were analyzed by year, age (on January 1 of the
year), sex, race, primary cause of ESRD, and hemoglobin
value. Patients who appeared in multiple years were
counted only once in the characteristic totals. The ex-
ceptions were totals by year and by modality, where one
patient may contribute to multiple years or modalities
(e.g., a 1998 and 1999 peritoneal dialysis patient who
became a 2000 hemodialysis patient).
Using 1996 to 2000 combined patients, the proportion
of time that patients had a hemoglobin value of ≥11 g/dL
was assessed by modality and age. To account for patients
appearing in multiple years, a patient-year method was
used. The follow-up time (≤1 year) was computed annu-
ally for each patient. Total patient years were then calcu-
lated as the total number of years (or fraction of a year)
of follow-up time for each modality and age group. Each
year, patients were classified as to whether or not they
attained a mean hemoglobin value of ≥11 g/dL. For each
modality and age, the total percentage of patient years
with a mean hemoglobin value of ≥11 g/dL was com-
puted. Values for pediatric (younger than age 20 years)
and adult patients (20 years old or older) within each
modality were compared with a test based on assumption
of a Poisson distribution. Methods were repeated to com-
pute and compare the percentage of patient years with in-
travenous iron. For patients with and without intravenous
iron, the distribution of patient years with a hemoglobin
value of ≥11 g/dL also was computed and comparisons
by treatment modality were made. In addition, the per-
centage of patient years with a mean hemoglobin value of
≥11 g/dL was computed for adult subgroups (20–44, 45–
64, and ≥65 years). Because pediatric patients may have
greater similarity to younger adults, values for pediatric
patients were compared to those of adults in the 20- to
44-year-old age group.
Trends in mean hemoglobin values were also identified
by age and year. For each year and treatment modality,
Bonferroni t tests were used to compare the pediatric
patients with adults. For 2000, mean hemoglobin values
were also calculated for the 20- to 44-, 45- to 64-, and
≥65-year-old adult groups, and pediatric and 20- to
44-year-old adult patients were compared using a t test.
For the year 2000, trends in mean hemoglobin values
were also identified by age and sex. Within each modality,
the mean hemoglobin value was computed for each sex
and age group. Within each sex, Bonferroni t tests were
used to compare pediatric patients with adults. Methods
were repeated to compare whites with blacks (for other
races, the sample size was insufficient).
Within the period prevalent hemodialysis and peri-
toneal dialysis cohorts, the subset of incident patients
was analyzed. These patients were evaluated separately
using data from the Medical Evidence Report (Cen-
ters for Medicare & Medicaid Services Form 2728)
completed at initiation of dialysis. These data included
hematocrit value, body weight, and if the patient had re-
ceived rHuEPO before initiation of dialysis. We calcu-
lated the mean hemoglobin value at initiation of dialysis
for pediatric and adult patients (1996 to 2000) who did
and did not receive rHuEPO after initiation of dialysis
during the incident year of ESRD. Also, among unique
patients included in the 1996 to 2000 cohorts, we com-
pared the percentages of pediatric and adult patients who
were incident during the 5-year study period.
In 1996 to 2000 hemodialysis and peritoneal dialysis pa-
tients, the use of rHuEPO before initiation of dialysis was
evaluated in the subset of incident patients with complete
Medical Evidence Report data. The percentages of pedi-
atric and adult patients who received predialysis rHuEPO
were compared. The weekly rHuEPO dose per kg of body
weight (rHuEPO/kg) was also evaluated for the subset of
incident patients with a valid body weight measurement
(1 to 175 kg) recorded on the Medical Evidence Report
at initiation of dialysis. For each patient, rHuEPO dose
per week was calculated as the total units of rHuEPO
received during the follow-up time divided by the total
outpatient weeks. Because outpatient rHuEPO claims
are not generated during hospitalizations, outpatient
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Table 1. Percentages of 1996 to 2000 period-prevalent
rHuEPO-treated hemodialysis and peritoneal dialysis patients by sex,
race, and primary cause of ESRDa
Hemodialysis Peritoneal dialysis
Age years 0–19 ≥20 0–19 ≥20
Sex
Male 54.3 51.6 48.1 50.9
Female 45.7 48.4 51.9 49.1
Race
White 49.3 56.9 62.3 66.7
Black 40.8 37.0 25.6 26.7
Native American 2.2 1.7 2.0 1.7
Asian 4.0 3.1 5.0 3.7
Other 3.7 1.2 5.0 1.3
Primary cause of ESRD
Diabetes 1.3 40.4 – 36.0
Hypertension 6.0 29.1 3.5 24.4
Glomerulonephritis 34.9 10.7 38.0 17.4
Cystic kidney disease 2.1 2.4 4.7 3.4
Other urologic 5.6 1.9 6.0 1.7
Hemolytic uremic syndrome 1.8 0.1 2.5 0.2
Chronic interstitial nephritis 1.8 1.6 1.8 2.2
Lupus erythematosus 6.8 1.2 3.9 2.4
Renal hypoplasia, 7.9 0.1 10.7 0.3
dysplasia, oligonephronia
Congenital obstructive 7.3 0.3 5.7 0.3
uropathy
Hereditary nephritis, 2.1 0.1 – 0.4
Alport’s syndrome
Other/unknown/missing 22.3 12.1 21.1 11.4
Abbreviations are: rHuEPO, recombinant human erythropoietin; ESRD,
end-stage renal disease.
aValues represent percentages of 0- to 19- and ≥20-year-old hemodialysis
patients (N = 1692 and N = 352,291) and peritoneal dialysis patients (N = 597
and N = 39,136).
– Values for cells with fewer than 10 patients are suppressed.
weeks were computed as the total weeks of follow-
up, excluding hospital days, which were obtained from
Medicare institutional inpatient claims data. Weekly
rHuEPO/kg was then computed as rHuEPO dose per
week divided by body weight in kg. For hemodialysis and
peritoneal dialysis patients, mean weekly rHuEPO/kg
was calculated and compared between pediatric and adult
patients. Patient percentages were compared with the
Pearson chi-square test, hemoglobin values were com-
pared with the t test, and weekly rHuEPO/kg was com-
pared with the Wilcoxon rank-sum test.
RESULTS
Patient distributions
For the years 1996 to 2000 combined, 353,983 period-
prevalent hemodialysis and 39,733 peritoneal dialysis pa-
tients were rHuEPO-treated and included in the study
(Tables 1 and 2). Of these, 1692 (0.5%) and 597 (1.5%)
were pediatric hemodialysis and peritoneal dialysis pa-
tients, respectively. For the year 2000, among pedi-
atric patients, the included rHuEPO-treated patients
represented 89.5% and 36.2% of all period-prevalent
pediatric hemodialysis and peritoneal dialysis patients,
respectively; among adults, 94.1% and 57.6%.
The by-age distribution of patient years with a
hemoglobin value of ≥11 g/dL varied by modality (Fig. 1).
For hemodialysis patients, the percentage of patient years
with a hemoglobin value of ≥11 g/dL was lowest for pa-
tients aged 0 to 4 years and increased with age. However,
for peritoneal dialysis patients, the percentage had a U-
shaped appearance, decreasing from ages 0 to 4 years to
15 to 19 years, and then increasing in adults. Overall, for
pediatric and adult hemodialysis patients, the percent-
ages of patient years with a hemoglobin value of ≥11 g/
dL were 45.9% and 60.2%, respectively (P < 0.0001);
for peritoneal dialysis patients, 30.5% and 44.9% (P <
0.0001). For 1996 to 2000 patients combined, the percent-
age of patient years with a hemoglobin value of ≥11 g/dL
was lowest for pediatric patients, and increased with in-
creasing age in the adult groups. Respectively, for 20- to
44-, 45- to 64-, and ≥65-year-old adults, the percentages of
patient years with a hemoglobin value of ≥11 g/dL were
55.3%, 59.3%, and 62.5% for hemodialysis patients, and
34.7%, 44.0%, and 54.0% for peritoneal dialysis patients.
Percentages were significantly lower for pediatric pa-
tients than for 20- to 44-year-old adults among hemodial-
ysis (P < 0.0001) and among peritoneal dialysis patients
(P = 0.038).
The percentage of patient years with intravenous iron
was low, especially for younger patients and peritoneal
dialysis patients, and generally increased with age (Fig. 2).
Among pediatric and adult hemodialysis patients, intra-
venous iron was administered in 66.3% and 82.5% of
the patient years, respectively (P < 0.0001); among peri-
toneal dialysis patients, 14.7% and 20.3% (P = 0.001).
Also, for patients with and without intravenous iron, the
distribution of patient years with a hemoglobin value
of ≥11 g/dL varied by modality. Among adult patients
with and without intravenous iron, respectively, the per-
centages of patient years with a hemoglobin value of
≥11 g/dL were 61.5% and 54.0% among hemodialysis
patients (P < 0.0001), and 39.7% and 46.3% among
peritoneal dialysis patients (P < 0.0001). Among pedi-
atric patients, for those with and without intravenous
iron, respectively, the percentages of patient years with
a hemoglobin value of ≥11 g/dL were 49.1% and
39.6% among hemodialysis patients (P = 0.31), and
21.1% and 32.1% among peritoneal dialysis patients
(P = 0.03).
Trends in mean hemoglobin value by modality,
year, and age
Within each modality and year, the mean hemoglobin
value for pediatric patients was significantly lower than
that for adults (Fig. 3). However, hemoglobin values im-
proved in pediatric hemodialysis patients from 1996 to
2000 and in pediatric peritoneal dialysis patients after
1998.
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Table 2. Distributions of 1996 to 2000 period-prevalent rHuEPO-treated hemodialysis and peritoneal dialysis patients by hemoglobin, age, and
yeara
Hemodialysis Peritoneal dialysis
0–19 ≥20 0–19 ≥20
Age years N %N N %N N %N N %N
Hemoglobin g/dL
<9 99 5.9 9,695 2.8 106 17.8 2,786 7.1
9–9.9 209 12.4 27,587 7.8 124 20.8 6,042 15.4
10–10.9 541 32.0 107,270 30.4 205 34.3 13,920 35.6
11–11.9 657 38.8 164,502 46.7 113 18.9 12,265 31.3
≥12 186 11.0 43,237 12.3 49 8.2 4,123 10.5
Age years
0–4 56 3.3 – – 65 10.9 – –
5–9 95 5.6 – – 53 8.9 – –
10–14 281 16.6 – – 142 23.8 – –
15–19 1,260 74.5 – – 337 56.4 – –
20–44 – – 53,005 15.0 – – 10,090 25.8
45–64 – – 114,210 32.4 – – 14,736 37.7
≥65 – – 185,076 52.5 – – 14,310 36.6
Yearb
1996 570 33.7 146,190 41.5 224 37.5 15,715 40.2
1997 587 34.7 160,869 45.7 202 33.8 15,573 39.8
1998 615 36.3 171,058 48.6 177 29.6 13,232 33.8
1999 603 35.6 181,575 51.5 137 22.9 12,098 30.9
2000 599 35.4 190,467 54.1 134 22.4 11,149 28.5
rHuEPO is recombinant human erythropoietin.
aValues represent the number and percentage of 0- to 19- and ≥20-year-old hemodialysis patients (N = 1692 and N=352,291) and peritoneal dialysis patients (N =
597 and N = 39,136).
bPercentages across years sum to >100 because some patients appear in multiple years.
– Values for cells with fewer than 10 patients are suppressed.
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Fig. 1. Percentage of patient years with a hemoglobin (Hb) value
of ≥11 g/dL by modality and age, 1996 to 2000 (combined) period-
prevalent hemodialysis and peritoneal dialysis patients treated with re-
combinant human erythropoietin (rHuEPO). Each patient may con-
tribute <1 to 5 total patient years to a maximum of two age groups.
Hemoglobin values also increased with increasing age
among the adults. In 2000, the mean hemoglobin val-
ues for 0- to 19-, 20- to 44-, 45- to 64-, and ≥65-year-old
prevalent patients were 11.16, 11.42, 11.47, and 11.51 g/
dL for hemodialysis patients, and 10.76, 10.79, 11.13,
and 11.43 g/dL for peritoneal dialysis patients, respec-
tively. Although the mean hemoglobin value in 2000
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Fig. 2. Percentage of patient years with intravenous (IV) iron by
modality and age, 1996 to 2000 (combined) period-prevalent hemodial-
ysis and peritoneal dialysis patients treated with recombinant human
erythropoietin (rHuEPO). Each patient may contribute <1 to 5 total
patient years to a maximum of two age groups.
was lower among pediatric patients than among 20- to
44-year-old adult hemodialysis patients (P < 0.0001),
the difference between pediatric and 20- to 44-year-old
adult peritoneal dialysis patients was not significant (P =
0.81). Among adult hemodialysis and peritoneal dial-
ysis patients in 2000, the mean hemoglobin value was
significantly lower in 20- to 44-year-olds than in 45- to
64-year-olds, and in 45- to 64-year-olds than in ≥65-year-
olds (P < 0.0001).
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Fig. 3. Mean hemoglobin (Hb) value by
modality, year, and age, 1996 to 2000 period-
prevalent hemodialysis and peritoneal dialysis
patients treated with recombinant human ery-
thropoietin (rHuEPO). ∗P < 0.0001 in com-
parison with that year’s group aged ≥20 years;
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quired for significance to maintain an overall
P value of 0.05.
10
.6
10
.9
10
.7
†10
.91
1.
2*
11
.1
*
11
.1
*
11
.2
*
11
.3
11
.111
.31
1.
5
10
.9
11
.5
11
.4
11
.4
10.0
10.5
11.0
11.5
12.0
12.5
Male
N = 326
N = 98,388
Female
N = 273
N = 92,079
White
N = 286
N = 101,838
Black
N = 258
N = 76,362
Male
N = 54
N = 5474
Female
N = 80
N = 5675
White
N = 83
N = 7209
Black
N = 33
N = 3103
M
ea
n 
H
b 
va
lu
e,
 g
/d
L 0−19
20+
Age group
(years)
Hemodialysis patients Peritoneal dialysis patients
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prevalent hemodialysis and peritoneal dialysis
patients treated with recombinant human ery-
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of 0.05. “N” provides the number of patients
aged 0 to 19 and ≥20 years, respectively, in
each group.
Trends in mean hemoglobin value by age and
sex and by age and race
Among hemodialysis patients in 2000, pediatric pa-
tients had a significantly lower mean hemoglobin value
than that of same-sex and same-race adults (P < 0.0001)
(Fig. 4). Among peritoneal dialysis patients grouped by
sex and race, the trend of lower hemoglobin among pe-
diatric patients than adults appeared consistent; how-
ever, only the pediatric females had a significantly lower
hemoglobin value than that of female adults (P = 0.0061).
Among pediatric hemodialysis and peritoneal dialysis pa-
tients, respectively, mean hemoglobin values were 0.1
and 0.2 g/dL lower in females than in males, and 0.1
and 0.3 g/dL lower in black than in white patients. Mean
hemoglobin values were lowest in female pediatric peri-
toneal dialysis patients (10.7 g/dL) and in black pediatric
peritoneal dialysis patients (10.6 g/dL). The sex and racial
differences were not statistically significant (results not
shown).
Distributions in the subset of incident patients
In incident Medicare dialysis patients (1996 to 2000
combined) with and without rHuEPO during the inci-
dent year of ESRD, respectively, the mean hemoglobin
values at initiation of dialysis were as follows: for pedi-
atric hemodialysis patients, 8.7 and 8.3 g/dL (N = 421
and N = 78; P = 0.10); for adult hemodialysis patients,
9.5 and 9.7 g/dL (N = 146,948 and N = 24,621; P <
0.0001); for pediatric peritoneal dialysis patients, 8.4 and
9.0 g/dL (N = 135 and N = 270; P = 0.007); and for adult
peritoneal dialysis patients, 9.7 and 10.1 g/dL (N = 9352
and N = 9547; P < 0.0001). Among included rHuEPO-
treated patients (1996 to 2000 combined), the percentage
of patients who were incident sometime during the 5-year
study period was smaller for pediatric than for adult
hemodialysis patients (28.7% vs. 45.1%; P < 0.0001); per-
centages were similar for pediatric and adult peritoneal
dialysis patients who were incident (25.8% vs. 25.7%;
P = 0.94).
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We evaluated rHuEPO use before initiation of dialysis
in the subset of incident patients (1996 to 2000 combined)
with complete Medical Evidence Report data (N = 451
pediatric and N = 156,793 adult hemodialysis patients;
N = 147 pediatric and N = 9901 adult peritoneal dialysis
patients). For pediatric and adult patients, respectively,
predialysis rHuEPO was received in 24.6% and 24.9% of
hemodialysis patients (P = 0.88) and 27.9% and 35.0% of
peritoneal dialysis patients (P = 0.07). Also, we computed
the weekly rHuEPO/kg body weight during the incident
year of dialysis for the subset of incident patients with a
valid body weight measurement recorded on the Medi-
cal Evidence Report (N = 442 pediatric and N = 154,739
adult hemodialysis patients; N = 123 pediatric and N =
8837 adult peritoneal dialysis patients). For pediatric and
adult patients, respectively, the mean weekly rHuEPO/kg
body weight was 208 and 181 U/kg for hemodialysis pa-
tients (P = 0.009), and 121 and 77 U/kg for peritoneal
dialysis patients (P < 0.0001).
DISCUSSION
Our data show that a target hemoglobin value of ≥11 g/
dL was achieved a low percentage of the time among
Medicare pediatric patients receiving rHuEPO treatment
while on chronic dialysis. Among pediatric hemodialy-
sis patients, 0- to 4-year-old patients attained a target
hemoglobin value the lowest percentage of time, followed
by 5- to 9-year-olds. Among pediatric peritoneal dialysis
patients, 10- to 14-year-old and 15- to 19-year-old patients
achieved a target hemoglobin value the lowest percent-
age of time. Among pediatric patients within each modal-
ity, slightly lower mean hemoglobin values were found
among blacks than whites, and among females than males.
All patients in our study received rHuEPO after ini-
tiation of dialysis, which has been shown to correct
anemia in pediatric dialysis patients [10, 11, 14–16]. How-
ever, the target hemoglobin value was achieved in pedi-
atric hemodialysis patients in only 46% of patient years,
compared with 55% of patient years in young adults
and 60% of patient years in adults overall. The North
American Pediatric Renal Transplant Cooperative Study
(NAPRTCS) has reported findings very similar to ours.
The 2001 NAPRTCS annual report showed that 63% of
1855 pediatric chronic dialysis patients who were receiv-
ing rHuEPO at 6 months of dialysis had hematocrit values
of ≤33% (≤11 g/dL) [17]. This report, however, did not
include hemoglobin data, hematocrit data by type of dial-
ysis, or data on children under the age of 6 years who were
treated with hemodialysis and were receiving rHuEPO.
We did observe improvement in mean hemoglobin val-
ues between 1996 and 2000 for pediatric hemodialysis
patients and adult hemodialysis and peritoneal dialysis
patients. Pediatric peritoneal dialysis patients showed im-
provement between the years 1998 and 2000. However,
mean hemoglobin values in children lagged behind those
in adults at all time periods during the study. NAPRTCS
found that mean hematocrit values at 6 months of dialy-
sis improved with time, increasing from 31.2% in patients
who initiated dialysis between 1992 and 1996 to 32.3%
in patients who initiated dialysis between 1997 and 2000
(P < 0.001) [17]. Both our study and the NAPTRCS
report show that a significant percentage of pediatric
patients are below the National Kidney Foundation
Dialysis Outcomes Quality Initiative (K/DOQI) target
hemoglobin value of 11 g/dL.
The recommended starting dosage of rHuEPO is 50
to 150 U/kg, given three times weekly. We could not
determine the dosage given based on body weight for
the prevalent dialysis patients in this study because body
weight data were available only at initiation of dialysis.
However, in the small subset of incident patients with
a valid body weight measurement at initiation of dial-
ysis, we showed that pediatric hemodialysis and peri-
toneal dialysis patients received mean weekly rHuEPO
doses of 208 and 121 U/kg, respectively, and that these
doses were significantly higher than those received by
adults. Although the NAPRTCS report did not include
rHuEPO/kg, these results are consistent with the re-
sults of smaller pediatric studies showing higher rHuEPO
dose requirements in pediatric patients of small body
weight [14, 16, 18–21]. In the subset of incident patients
with an indication on the Medical Evidence Report of
rHuEPO use before dialysis, the percentages of patients
treated with rHuEPO were similar for pediatric and adult
hemodialysis patients, and were slightly, but not signifi-
cantly, lower in pediatric than in adult peritoneal dialysis
patients. In our study, lower rHuEPO use before dialy-
sis did not appear to be a major contributing factor to
lower hemoglobin values in pediatric hemodialysis pa-
tients. However, these results are limited due to the small
subset of incident patients with available data.
Fewer pediatric than adult patients were treated with
rHuEPO after initiation of dialysis. Our subset analysis of
incident patients showed higher mean hemoglobin values
at initiation of dialysis in pediatric and adult peritoneal
dialysis patients and adult hemodialysis patients who did
not receive rHuEPO during the incident year of ESRD.
Still, the mean hemoglobin values for the untreated group
were below the target value in the K/DOQI guidelines,
suggesting less than optimal management.
The lowest hemoglobin values were observed in young
peritoneal dialysis patients. Studies of pediatric dialysis
patients have suggested that patient age, size, and dial-
ysis type are factors in the response to rHuEPO[14, 18–
21]. A study of 116 pediatric hemodialysis patients found
that children weighing less than 30 kg required twice
the dose of rHuEPO (225 U/kg per week vs. 107 U/
kg per week) as those weighing more than 30 kg to
reach a hemoglobin value of 9.6 g/dL[ 14]. Two studies
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of pediatric patients (one of 23 hemodialysis and 30 peri-
toneal dialysis patients; the other of 9 hemodialysis and
10 peritoneal dialysis patients) found that rHuEPO re-
quirements were nearly three times higher in hemodialy-
sis than in peritoneal dialysis patients [19, 20]. Our finding
of lower hemoglobin values in pediatric peritoneal dial-
ysis patients compared to hemodialysis patients could be
related to a possible selection bias due to inclusion of
only rHuEPO-treated patients. A smaller percentage of
peritoneal dialysis (36.2%) versus hemodialysis (89.5%)
patients were rHuEPO-treated and included in the study.
Our finding of lower hemoglobin values in pediatric pa-
tients could not be attributed to a greater percentage of
incident pediatric patients than adult patients in each cal-
endar year. The period-prevalent cohort analysis showed
that a smaller percentage of the pediatric hemodialy-
sis patients than adult patients were incident sometime
during the 5-year study period. Among peritoneal dial-
ysis patients, similar percentages of pediatric and adult
patients were incident.
Sex and racial differences in rHuEPO responsiveness
have been reported in adults [22–24]. In a study of
309 adult hemodialysis patients (165 women, 144 men),
women required a 39% higher rHuEPO dose to achieve
hematocrit values comparable to those in men; because
women and men received equivalent amounts of in-
travenous iron, the difference in rHuEPO requirement
was attributed to the contribution of androgens to ery-
thropoiesis [22]. In our study, mean hemoglobin values
were lower in females than in age-matched males and in
blacks than in age-matched whites, irrespective of dial-
ysis type, although the differences were not statistically
significant.
Iron deficiency (functional or absolute) is common in
rHuEPO-treated ESRD patients; accordingly, these pa-
tients require iron supplementation [8, 13, 18, 25–29].
Thus, among pediatric hemodialysis and peritoneal dial-
ysis patients, it is of concern that intravenous iron was not
administered during 34% and 85% of the patient years,
respectively. We found the use of intravenous iron to be
lowest in patients aged 0 to 4 years, irrespective of dial-
ysis type. Among patients aged 0 to 4 years, intravenous
iron was received during only 33.9% (hemodialysis) and
0.3% (peritoneal dialysis) of the patient years. Although
intravenous iron use increased for peritoneal dialysis pa-
tients 5 years of age or older, it was used much less than
in hemodialysis patients. However, pediatric peritoneal
dialysis patients likely received oral iron supplementa-
tion. The 2001 NAPRTCS annual report showed that
most pediatric chronic dialysis patients at 12 months of
dialysis were receiving oral iron supplementation (84%
of peritoneal dialysis and 72% of hemodialysis patients)
[17]. Attention to iron management provides an opportu-
nity to improve anemia profiles in pediatric chronic dial-
ysis patients.
The current suggested target hemoglobin range in
adults and pediatric patients with ESRD is 11 to 12 g/dL
[12]. Despite the publication of guidelines in 1997 [12], pe-
diatric peritoneal dialysis patients from 1998 to 2000 and
pediatric hemodialysis patients in 1998 did not achieve
a mean hemoglobin value in the target range. Recent
improvements in mean hemoglobin values in rHuEPO-
treated pediatric hemodialysis patients have exceeded
those in rHuEPO-treated pediatric peritoneal dialysis
patients.
In adult chronic dialysis patients, anemia has been
shown to be a risk factor for the development of left ven-
tricular hypertrophy, cardiomyopathy, and death [3, 4, 23,
30–36]. No large, prospective studies in pediatric chronic
dialysis patients have linked anemia to outcomes such as
cardiovascular disease, the leading cause of mortality in
adults and children with ESRD [4, 5, 37, 38]. In a small
study of the effects of anemia on cardiovascular abnor-
malities in 7 children on chronic dialysis, Morris et al [9]
found that treatment of anemia with rHuEPO was asso-
ciated with improvement in left ventricular hypertrophy.
After 12 months of treatment the mean hemoglobin had
improved from 7.2 g/dL to 11.7 g/dL (P < 0.01), left ven-
tricular mass index had decreased from 94 to 81 g/m2 (P =
0.02), and the mean cardiothoracic ratio had decreased
from 50% to 46% (P = 0.005) [9]. Recent studies show
cardiovascular disease is a significant cause of morbidity
and mortality in children with ESRD [5, 37, 38]. Thirty-
one percent of 1454 pediatric dialysis patients from 1991
to 1996 in the United States developed cardiovascular
disease, and it accounted for 38% of the deaths in these
patients [5]. In a study of 381 prevalent pediatric chronic
dialysis patients from The Netherlands, cardiac disease
accounted for 45% of the patient deaths [37]. Parekh et al
[38] found that cardiovascular disease accounted for 23%
of 1380 deaths in United States pediatric and young adult
ESRD patients who died between 1990 and 1996. These
findings suggest the need for a large, prospective study
of cardiovascular disease risk factors such as anemia in
children with ESRD.
Approximately 55% of 1996 to 1998 incident pediatric
ESRD patients received a kidney transplant within two
years after starting ESRD therapy [24]. Therefore, the
pediatric chronic dialysis patients in this study may have
represented a pediatric population with comorbid condi-
tions that prevented them from undergoing transplanta-
tion in a timely manner. This potential selection bias may
in part explain the degree of anemia found in pediatric
patients in this study.
CONCLUSION
Pediatric chronic dialysis patients in the United States
may be undertreated for anemia despite the use of
rHuEPO supplementation. We found this to be especially
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true for black and female patients. Intravenous iron may
also be underused in pediatric chronic dialysis patients.
Although mean hemoglobin values in pediatric patients
lagged behind values in adults across years, we saw a def-
inite trend toward improved mean hemoglobin values in
children over time. The results of this study indicate the
need for continued improvement in the management of
anemia in children undergoing chronic dialysis.
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